Lip Cancer
8
3
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Integrated Cancer Repository for Cancer Research
Microbiome in Head and Neck Squamous Cell Carcinoma
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Serum Lipid Profile and Lip Squamous Cell Carcinoma
T1 Squamous Cell Carcinomas of the Lip
Nicotine Levels With Response Rates to Radiation Alone or With Chemo In Head & Neck Cancer
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations